Free Trial
OTCMKTS:BIOQ

Bioqual (BIOQ) Stock Price, News & Analysis

Bioqual logo
$62.50 -2.50 (-3.85%)
As of 01/21/2025 10:27 AM Eastern

About Bioqual Stock (OTCMKTS:BIOQ)

Key Stats

Today's Range
$62.50
$62.50
50-Day Range
$62.50
$67.50
52-Week Range
$62.50
$80.00
Volume
250 shs
Average Volume
225 shs
Market Capitalization
$55.63 million
P/E Ratio
N/A
Dividend Yield
0.80%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

Receive BIOQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioqual and its competitors with MarketBeat's FREE daily newsletter.

BIOQ Stock News Headlines

BIOQUAL Announces Changes to Board of Directors
Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
BIOQUAL Declares Dividend
SEC rules Fox can skip vote on labeling TV opinion shows
BIOQUAL Presents Financial Results for Fiscal Year 2024
See More Headlines

BIOQ Stock Analysis - Frequently Asked Questions

Bioqual's stock was trading at $66.10 at the beginning of the year. Since then, BIOQ stock has decreased by 5.4% and is now trading at $62.50.
View the best growth stocks for 2025 here
.

Bioqual, Inc. (OTCMKTS:BIOQ) announced its quarterly earnings data on Tuesday, January, 21st. The company reported ($1.36) EPS for the quarter. Bioqual had a negative trailing twelve-month return on equity of 2.87% and a negative net margin of 1.99%.

Shares of BIOQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioqual investors own include Zymergen (ZY), Allied Gaming & Entertainment (AGAE), Align Technology (ALGN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO) and Berkeley Energia (BKY).

Company Calendar

Ex-Dividend for 10/28 Dividend
10/07/2024
Dividend Payable
10/28/2024
Today
1/21/2025
Last Earnings
1/21/2025
Next Earnings (Estimated)
1/21/2025
Fiscal Year End
5/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
OTCMKTS:BIOQ
CUSIP
09065J101
Fax
N/A
Employees
114
Year Founded
N/A

Profitability

Net Income
$480,000.00
Pretax Margin
-3.10%

Debt

Sales & Book Value

Annual Sales
$58.59 million

Miscellaneous

Free Float
543,000
Market Cap
$55.63 million
Optionable
Not Optionable
Beta
-0.33
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:BIOQ) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners